Acumen Pharmaceuticals (ABOS) Long-Term Investments (2021 - 2025)

Acumen Pharmaceuticals has reported Long-Term Investments for 5 years, with the latest figure at $9.4 million in Q3 2025.

• Quarterly Long-Term Investments fell 83.87% year-over-year to $9.4 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $9.4 million (down 83.87% YoY) and the FY2024 annual result came in at $60.0 million, down 4.13% from the prior year.
• Long-Term Investments declined to $9.4 million in Q3 2025 per ABOS's latest filing, from $22.8 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $67.3 million in Q3 2023 and troughed at $9.4 million in Q3 2025.
• A 5-year average of $36.9 million and a median of $30.8 million in 2021 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2023 and 2025: Long-Term Investments jumped 294.98% in 2023, then sank 83.87% in 2025.
• Over 5 years, Long-Term Investments stood at $31.6 million in 2021, then tumbled by 49.91% to $15.8 million in 2022, then surged by 294.98% to $62.6 million in 2023, then fell by 4.13% to $60.0 million in 2024, then plunged by 84.25% to $9.4 million in 2025.
• According to Business Quant data, Long-Term Investments over the past three periods registered $9.4 million, $22.8 million, and $48.8 million for Q3 2025, Q2 2025, and Q1 2025 respectively.